Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA gyrase subunit B

3

DNA topoisomerase II

3

HSP90

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1956

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

3

Breast cancer

3

Non-small cell lung cancer

3

Psoriasis

3

Staphylococcal Infections

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

3

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer|Upjohn

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ChEMBL

3

ECHA (EC/EINECS)

3

FDA UNII

3

NCI_THESAURUS

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

NOVOBIOCIN

17EC19951N

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1956

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA gyrase subunit B

Conditions:

Non-small cell lung cancer

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

Staphylococcal Infections

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was w...

ithdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

NOVOBIOCIN SODIUM

Q9S9NQ5YIY

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1956

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA gyrase subunit B

Conditions:

Non-small cell lung cancer

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

Staphylococcal Infections

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was w...

ithdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

NOVOBIOCIN CALCIUM

RHW5BU180N

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1956

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA topoisomerase II

DNA gyrase subunit B

Conditions:

Non-small cell lung cancer

Bovine subclinical mastitis caused by Staphylococcus aureus and Streptococcus agalactiae

Staphylococcal Infections

Novobiocin (also known as streptonivicin) is an aminocoumarin antibiotic, active against Staphylococcus epidermidis. Novobiocin and other aminocoumarin antibiotics act as a potent competitive inhibitor of DNA gyrase B. The oral form of the drug was w...

ithdrawn from the market in 1999 due to safety or effectiveness reasons. Later it was discovered that novobiocin inhibited Hsp90 and topoisomerase II, and novobiocin was investigated in clinical trials against metastatic breast cancer and non-small cell lung cancer. Topical form of novobiocin was investigated in combination with nalidixic acid for treatment of psoriasis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1